Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature

Ono, Shin; Suzuki, Yutaro; Shindo, Masanobu; Endo, Toshiya; Fukui, Naoki; Sugai, Takuro; Someya, Toshiyuki

doi:10.1111/j.1365-2710.2011.01290.x

Cited by 19 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Risperidone demonstrated a much higher tolerability, as 33% (7/21) of the aripiprazole treated patients dropped out before the end of the 22‐day trial (0% drop out for risperidone, 0/21). Treatment with aripiprazole resulted in significantly more akathisia and agitation in patients, contradicting biologically expected results, but consistent with a growing body of literature (Ono et al, ; Samiei et al, ). Surprisingly, although both risperidone and aripiprazole reduced cravings, the effect was significantly greater in risperidone‐treated subjects.…”

Section: Treatment Of Mapsupporting

confidence: 64%

Methamphetamine‐associated psychosis: Clinical presentation, biological basis, and treatment options

Chiang

Lombardi

et al. 2019

Human Psychopharmacology

View full text Add to dashboard Cite

Introduction Methamphetamine associated psychosis (MAP) represents a mental disorder induced by chronic methamphetamine use in a subset of users. The prevalence of the disorder has increased in several countries in Europe and Asia where methamphetamine use has increased. MAP remains difficult to distinguish from primary psychiatric disorders, especially schizophrenia, creating complications in prescribing treatment plans to patients. Design This narrative review sought to summarize difficulties related to MAP diagnosis and highlight the need for a better treatment model. Current best practices are described and potential novel therapies and future research suggested. Results Results suggest that clear biological and clinical differences appear between patients presenting with MAP and schizophrenia and that there may exist distinct subgroups within MAP itself. MAP‐specific treatment studies have been few and have focused on the use of antipsychotic medication. Antipsychotic treatment has been shown to alleviate the psychotic symptoms of MAP but produce debilitating adverse effects and fail to adequately address methamphetamine use in patients. Conclusions Continued identification of subgroups within the heterogenous MAP population may lead to better diagnosis, treatment, and outcomes for patients. Psychosocial therapies should be explored in addressing the cooccurring substance use and psychosis in the treatment of MAP.

show abstract

Section: Treatment Of Mapsupporting

confidence: 64%

Methamphetamine‐associated psychosis: Clinical presentation, biological basis, and treatment options

Chiang

Lombardi

et al. 2019

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…The suppressive effects of first-generation neuroleptics on TD can be substantial (>60 % improvement), but several studies have suggested that this is only a temporary effect [25,59], triggering a spiraling of the dose upwards over time. The SGAs quetiapine, clozapine, risperidone, and olanzapine [60][61][62][63][64] have also been used to treat TD with similarly unknown efficacy and safety in the long term [21]. Other long-term studies do not support the ability of SGAs to suppress TD [46].…”

Section: Should Neuroleptics Be Used As a Therapeutic Agent For Td?mentioning

confidence: 99%

Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder

2014

View full text Add to dashboard Cite

Tardive dyskinesia (TD) is a serious, often disabling, movement disorder that is caused by medications that block dopamine receptors (i.e., neuroleptics, anti-emetics). There is currently no standard treatment approach for physicians confronted with such patients. This may be the result of notions that TD is disappearing because of the switch to secondgeneration antipsychotic agents and that it is largely reversible.In this article we demonstrate that second-generation antipsychotics do, indeed, cause TD and, in fact, the frequency is likely higher than expected because of growing off-label uses and a tripling of prescriptions written in the last 10 years. In addition, studies demonstrate that TD actually remits in only a minority of patients when these drugs are withdrawn. Furthermore, neuroleptic agents are often utilized to treat TD, despite prolonged exposure being a risk factor for irreversibility. The outcome of these trends is a growing population afflicted with TD. We review non-neuroleptic agents that have shown positive results in small, early-phase, blinded trials, including tetrabenazine, amantadine, levetiracetam, piracetam, clonazepam, propranolol, vitamin B6, and Ginkgo biloba. Other options, such as botulinum toxin and deep brain stimulation, will also be discussed, and a suggested treatment algorithm is provided. While these agents are reasonable treatment options at this time there is a need, with a concerted effort between neurology and psychiatry, for full-scale drug development, including multicenter, randomized, blinded trials to confirm the effectiveness of the agents that were positive in phase 2 trials and the development of newer ones.

show abstract

“…Quetiapine-related TD was noted and described in an early case report about 15 years ago 5). However, some reports also mention contrary findings of quetiapine's ability to relieve TD 1,2,8,9,10,11,12,13). Emsley et al14) found that quetiapine could effectively reduce TD severity in patients with established TD, but the mechanism of this action is unclear.…”

Section: Discussionmentioning

confidence: 99%

Late-onset Quetiapine-related Tardive Dyskinesia Side Effects in a Patient with Psychotic Depression

Hou

Lai

2014

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

The atypical antipsychotics were believed to induce less extrapyramidal syndrome, including tardive dyskinesia (TD). Since the introduction of the quetiapine, it is also reported with less TD side effects. It even can relieve the symptoms of severe TD and reduce the risk of TD. The quetiapine's low affinity and fast dissociation from postsynaptic dopamine D2 receptors should give the least risk of producing the symptoms of TD. The quetiapine even can reduce the TD side effects related to clozapine, which has the lowest risk for TD. However, since the first case report of TD side effects related to quetiapine published on 1999, the safety of quetiapine in TD aspect has been questioned. Therefore, we want to share this case report, which was written to describe the severe late-onset TD side effects after long-term use of quetiapine in a patient with psychotic depression. The patient had no significant findings after concurrent comprehensive neurological examinations, magnetic resonance imaging of brain and electroencephalogram since the onset of TD.

show abstract

Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature

Cited by 19 publications

References 24 publications

Methamphetamine‐associated psychosis: Clinical presentation, biological basis, and treatment options

Methamphetamine‐associated psychosis: Clinical presentation, biological basis, and treatment options

Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder

Late-onset Quetiapine-related Tardive Dyskinesia Side Effects in a Patient with Psychotic Depression

Contact Info

Product

Resources

About